7-hydroxymitragynine
Sign in to save7-Hydroxymitragynine (7-OH-MIT, often simply referred to as 7-OH) is a terpenoid indole alkaloid present in the plant Mitragyna speciosa (the leaves of which are commonly known as kratom). It was first described in 1994. In humans, it is produced as an active metabolite of mitragynine via hepatic oxidation.
Key facts
- Drug.drug_name
- 7-Hydroxymitragynine
- Drug.IUPAC_name
- Methyl (2E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
- Drug.image
- 7-hydroxymitragynine2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- 7-OH-mitragynine.png
- Drug.image_class2
- bg-transparent
- Drug.legal_BR
- F1
- Drug.legal_US
- Unscheduled
- Drug.dependency_liability
- High
- Drug.addiction_liability
- High
- Drug.routes_of_administration
- Oral
- Drug.metabolites
- Mitragynine pseudoindoxyl
- Drug.CAS_number
- 174418-82-7
- Drug.ATC_prefix
- None
- Drug.PubChem
- 44301524
- Drug.ChemSpiderID
- 23152144
- Drug.UNII
- 2T3TWA75R0
- Drug.ChEMBL
- 61630
via Wikipedia infobox
Wikidata facts
- Mass
- 414.215
Show 4 more facts
- chemical formula
- C₂₃H₃₀N₂O₅
- canonical SMILES
- CCC1CN2CCC3(C(=NC4=C3C(=CC=C4)OC)C2CC1C(=COC)C(=O)OC)O
- isomeric SMILES
- CC[C@@H]1CN2CC[C@]3(C(=NC4=C3C(=CC=C4)OC)[C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)O
- Commons category
- 7-Hydroxymitragynine
Sources (2)
via Wikidata · CC0
~2 min read
Article
8 sectionsContents
- Pharmacology
- Synthesis
- Society and culture
- Legal status
- United States
- Research
- See also
- References
7-Hydroxymitragynine (7-OH-MIT, often simply referred to as 7-OH) is a terpenoid indole alkaloid present in the plant Mitragyna speciosa (the leaves of which are commonly known as kratom). It was first described in 1994. In humans, it is produced as an active metabolite of mitragynine via hepatic oxidation.
7-OH exhibits greater binding affinity to μ-opioid receptors (MOR) than mitragynine. It acts primarily as a partial agonist at μ-opioid receptors while antagonizing δ- and κ-opioid receptors; unlike traditional opioids, it appears not to recruit the β-arrestin pathway, which may influence its side effect profile.